Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.66 |
| ▸ | CA2 | P00918 | 9/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17879683 | 1.00 | CA1 (0.66) | CA1CA2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL13589983 | 0.93 | CA1 (0.68) | CA1CA2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL3093075 | 0.93 | CA1 (0.68) | CA1CA2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL17879702 | 0.92 | CA1 (0.62) | CA1CA2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL9162085 | 0.92 | CA1 (0.68) | CA1CA2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL17879692 | 0.90 | CA1 (0.60) | CA1CA2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL17879694 | 0.89 | CA1 (0.55) | CA1CA2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL339168 | 0.87 | ALDH1A1 (0.61) | CA1CA2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL17879689 | 0.87 | L3MBTL1 (0.57) | CA1CA2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL17883376 | 0.87 | CA1 (0.53) | CA1CA2ALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217452-A1 | CONSTRAINED IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025217454-A2 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-10001584-B2 | Optical film, and polarizing plate and liquid crystal display device that use this optical film | FUJIFILM CORPORATION (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10001584-B2 | Optical film, and polarizing plate and liquid crystal display device that use this optical film | FUJIFILM CORPORATION (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20160187537-A1 | OPTICAL FILM, AND POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE THAT USE THIS OPTICAL FILM | FUJIFILM CORPORATION (JP) | 2016-06-30 | — | — | US | disclosed |
| US-20160187537-A1 | OPTICAL FILM, AND POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE THAT USE THIS OPTICAL FILM | FUJIFILM CORPORATION (JP) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | CA1 1603/4885CA2 1661/4885ALDH1A1 4869/4885 |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | CA1 1603/4885CA2 1661/4885ALDH1A1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.